CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 17, 2006--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY - News), a leading RNAi therapeutics company, announced today that it has entered into a collaboration with University of Texas (UT) Southwestern Medical Center at Dallas to evaluate new approaches for reducing LDL-cholesterol levels using RNAi therapeutics directed to a disease target called proprotein convertase subtilisn/kexin type 9, or PCSK9.
